Ellex Medical Lasers’ (ASX:ELX) research collaborator Professor Erica Fletcher from the University of Melbourne has been awarded a $355,000 Australian Research Council (ARC) Linkage grant.
The funds will be used to detail the precise effects its 2RT laser has on cells, cell populations and the body as a whole.
It will provide fundamental knowledge on the impact of 2RT™on cell biology of immune cells and cell signalling pathways in the retina.
The work will also give Ellex’s researchers a better understanding of the mechanism of action and potential uses of the 2RT laser currently in use in clinical trials for the treatment of early-stage age-related macular degeneration.
During FY2015, sales of commercial 2RT units increased to early adopters and research collaborators in Holland, Germany, Italy, France, New Zealand and Australia.
As of 15th June 2015, these commercial 2RT units had been used to perform approximately 1,500 procedures on 940 patients. These patients and treatments are in addition to the patients being treated in the LEAD trial.
The potential market for AMS across the U.S., UK, Germany, France, Spain, Italy and Japan will almost double in value to $10.1 billion by 2023 from $5.1 billion in 2013.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.